Dr. Simkins is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
350 Oyster Point Blvd
South San Francisco, CA 94080Phone+1 517-303-4010
Summary
- I am a physician-scientist (D.O., Ph.D.) with a passion for understanding and developing ideas that will translate to therapies benefiting patients. With my extensive background in both clinical medicine and research, I am uniquely positioned to understand and drive science that will translate to therapies meeting clinical needs in any area of medicine. My passion for unraveling the complexities of the nervous system and autoimmunity (APBN Board Certified Neurologist with fellowship training in Multiple Sclerosis and Neuroimmunology) aligns seamlessly with the pursuit of therapeutic breakthroughs. My commitment to improving patient outcomes and advancing scientific knowledge makes me an invaluable asset in the dynamic landscape of pharmaceutical research and development.
Clinical Expertise
- Concussion, Traumatic brain injury, Post-concussive syndrome, Neurology, Post-concussion headaches, Musculoskeletal disorders, Neuroimmunology (Multiple sclerosis), Neuroimmunomodulation, Cannabinoids
Education & Training
Oregon Health & Science UniversityFellowship, Neuroimmunology & Multiple Sclerosis, 2019 - 2021
University of California Davis HealthChief Residency, Neurology, 2018 - 2019- University of California Davis HealthResidency, Neurology, 2015 - 2019
- University of California Davis HealthInternship, Preliminary Year, 2015 - 2016
Michigan State University College of Osteopathic MedicineClass of 2015
Michigan State UniversityPhD, Neuroscience & Environmental Toxicology, 2007 - 2014
Work Experience
- Cytokinetics, Inc.Medical Director, Clinical Research · March 2024 - Current
- Tyrell J Simkins, DO, PhD, PCCeo And Managing Director · October 2023 - Current
- Cytokinetics, Inc.Associate Medical Director · March 2022 - March 2024
- St Charles Health SystemNeurologist · October 2020 - June 2021
Certifications & Licensure
OR State License 2019 - 2025
CA State License 2017 - 2024- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) Start of enrollment: 2022 Jul 25
- A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Start of enrollment: 2021 Aug 16
- A Study to Evaluate the Effect of Aficamten in Pediatric Patients (Age 12 to <18 Years) With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). Start of enrollment: 2024 May 01
- Join now to see all
Publications & Presentations
PubMed
- Plasma neurofilament analysis in VITALITY-ALS.Tyrell J Simkins, Stuart Kupfer, Fady I Malik, Lisa Meng, Stacy A Rudnicki
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2024-11-08 - FBXW7 regulates MYRF levels to control myelin capacity and homeostasis in the adult CNS.Hannah Y Collins, Ryan A Doan, Jiaxing Li, Jason E Early, Megan E Madden
Biorxiv. 2024-10-17 - 4 citationsCOURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success.Jeremy M Shefner, Ammar Al-Chalabi, Jinsy A Andrews, Adriano Chio, Mamede De Carvalho
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration. 2023-08-01
Professional Memberships
- Member
- Society for NeuroscienceMember
- Member
- American Neurologic AssociationMember
- Sigma XiMember
- American Board of Psychiatry and NeurologyMember
External Links
- LinkedInhttps://www.linkedin.com/in/tyrell-simkins-do-phd/
- Cytokineticshttps://cytokinetics.com/
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
